Sodium-glucose cotransporter 2（ SGLT-2） inhibitor is a kind of new oral drug for the treatment of type2 diabetes. SGLT-2 inhibitors increase urinary glucose excretion by lowering the renal glucose threshold while expelling some energy. The hypoglycemic mechanism of SGLT-2 inhibitors depends on the difference in glucose concentration in blood and urine

when the blood sugar is lower

its effectiveness is greatly weakened

and the risk of hypoglycemia decreased. In addition to lowering blood sugar

SGLT-2 inhibitors have many benefits

including lowering systolic and diastolic blood pressure

altering hemodynamics

increasing hematocrit

reducing body mass

reducing visceral and subcutaneous fat

reducing uric acid

and protecting the heart and kidney. This paper reviews the drug interactions of the SGLT-2 inhibitors empagliflozin

dapagliflozin and canagliflozin that are approved for use in China

so as to provide reference for rational drug use by clinicians and pharmacists.